|
| Home » Industry Services » Health Care |
| Health Care |
Religare Technologies is poised to be a leader in the global IT space by pursuing aggressive business interests in key verticals. Our Health Care and Life Sciences (HLS) solutions and services are offered with a vision – “Creating an Integrated Health Care Delivery system”.
We have competitively strengthened ourselves with deep understanding of Domestic and International Market needs. Teamed with Domain experts, technocrats and professionals with Vendor Market understanding, it helps our customers to meet their business demands by architecting the required solutions.
At Religare Technologies, we appreciate business demands of our customers and propose the
“Best –in–class–cost effective–solutions”.
Our main focus lies on Optimization of functionalities resulting in enhanced end user work-flow by promising value add improvement to their previous experiences.
We commit to take this relationship throughout the implementation lifecycle and beyond. Some of the industry trends in Health Care and life sciences market are: |
| |
 |
Recession has hit the world market as a whole and changed the macroeconomics and business dynamics for ever; Health Care industry is not recession-proof though in better shape compared to other verticals |
| |
|
Interdependency between Payor, Provider and Pharma necessitates IT solutions across blurring lines of business |
| |
|
Pharma: Just-In-Time manufacturing, novel delivery methods and direct to consumer distribution will be adapted from other industries like the automotive industry |
| |
|
Health Care policy-makers and payors are increasingly mandating or influencing what doctors can prescribe |
| |
|
Regulations in Health Care like Medicare part D and universal coverage directly impacts pricing of drugs in the US |
| |
|
The markets of the developing world, where demand for medicines is likely to grow most rapidly over the next 13 years, are highly varied |
| |
|
Many governments are beginning to focus on prevention rather than treatment |
| |
|
The regulators are becoming more risk-averse |
|
|
|
